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Abstract
HIV substantially worsens human papillomavirus (HPV) carcinogenicity and contrib-
utes to an important population excess of cervical cancer, particularly in sub-
Saharan Africa (SSA). We estimated HIV- and age-stratified cervical cancer burden
at a country, regional and global level in 2020. Proportions of cervical cancer
(a) diagnosed in women living with HIV (WLHIV), and (b) attributable to HIV, were
calculated using age-specific estimates of HIV prevalence (UNAIDS) and relative
risk. These proportions were validated against empirical data and applied to age-
specific cervical cancer incidence (GLOBOCAN 2020). HIV was most important in
SSA, where 24.9% of cervical cancers were diagnosed in WLHIV, and 20.4% were
attributable to HIV (vs 1.3% and 1.1%, respectively, in the rest of the world). In all
world regions, contribution of HIV to cervical cancer was far higher in younger
women (as seen also in empirical series). For example, in Southern Africa, where
more than half of cervical cancers were diagnosed in WLHIV, the HIV-attributable
fraction decreased from 86% in women ≤34 years to only 12% in women
≥55 years. The absolute burden of HIV-attributable cervical cancer (approximately
28 000 cases globally) also shifted toward younger women: in Southern Africa, 63%
of 5341 HIV-attributable cervical cancer occurred in women <45 years old, com-
pared to only 17% of 6901 non-HIV-attributable cervical cancer. Improved quantifi-
cation of cervical cancer burden by age and HIV status can inform cervical cancer
prevention efforts in SSA, including prediction of the impact of WLHIV-targeted vs
general population approaches to cervical screening, and impact of HIV prevention.
K E YWORD S
age-specific incidence rates, cervical cancer, HIV, population-attributable fraction,
sub-Saharan Africa
What's new?
The cancer-causing potential of human papillomavirus (HPV) is amplified in patients infected with
HIV. This is a particular consideration in sub-Saharan Africa. Here, the authors developed an age-
specific method to determine the global burden of cervical cancer cases attributable to HIV. They
found that around 20% of cervical cancer cases in sub-Saharan Africa were attributable to HIV.
Most of these occurred in women under age 45. These data can inform design of cervical cancer
prevention programs, particularly in settings hit by a double burden of HPV and HIV.
1 | INTRODUCTION
Cervical cancer is a major public health problem, representing the
fourth most common cancer in women worldwide and accounting for
more than 600 000 new cases and 340 000 global deaths in 2020
(GLOBOCAN 2020 database presented in Global Cancer Observatory
proposed by the International Agency for Research on Cancer [IARC]:
https://gco.iarc.fr/today/home).1 However, this burden is unequally
distributed, with 9 out of 10 deaths from cervical cancer occurring in
low- and middle-income countries (LMIC), and 6 of those in sub-
Saharan Africa (SSA) alone.1 This inequality is partly a product of lack
of access to cervical cancer screening and cancer treatment, but also
of disparate prevalence of risk factors, including high-risk human pap-
illomavirus (HR HPV) and HIV infection.
Persistent infection with HR HPV types is the underlying cause of
all cervical cancer. However, natural history of HR HPV infection is
substantially worsened by HIV-related immunodeficiency, such that
women living with HIV (WLHIV) are at elevated cervical cancer risk. In
a recent systematic literature review and meta-analysis, HIV was esti-
mated to increase cervical cancer risk 6-fold and, in a subsequent
modeling exercise, to account for approximately 5% of the global cer-
vical cancer burden.2 HIV-attributable cervical cancer burden is partic-
ularly unequally spread, with 85% of cases diagnosed in SSA alone. In
Southern Africa, the SSA region most impacted by the HIV epidemic,
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more than half of all cervical cancer cases in 2018 were estimated to
be attributable to HIV.2
In 2020, the World Health Organization (WHO) launched a global
call to eliminate cervical cancer as a public health problem, for which
the main prevention components are HPV vaccination, cervical cancer
screening and management of detected disease.3 However, in settings
doubly hit by both HPV and HIV epidemics, most notably SSA, pro-
gress toward the cervical cancer elimination goal will also be
influenced by HIV-focused prevention measures, such as reducing
HIV prevalence, early diagnosis of HIV and timely initiation of combi-
nation antiretroviral therapy (cART). In these settings, age-specific
estimates of cervical cancer by HIV status are key to informing the
design of appropriate cervical cancer control programs (including the
extent to which cervical screening should be prioritized and adapted
for WLHIV), as well as to predict their impact.
There has been no previous description of the interaction of HIV
infection and age on cervical cancer at a population level. Such an
effort has been complicated by the changing epidemiology of the HIV
epidemic, first in terms of changing HIV prevalence, but even more so
by huge fluctuations in life expectancy due to severe co-mortality
from opportunistic infections (ie, decrease in life expectancy in the
early phases of the epidemic, followed by a subsequent increase in
the era of wider and earlier access to cART). Indeed, age-specific esti-
mates of HIV-attributable cervical cancer were considered beyond the
scope of the above-mentioned meta-analysis and global modeling
exercise,2 in recognition of the need for a more targeted approach.
To this end, our aim had two parts: first, to develop a methodology
to describe the relative contribution of HIV to age-specific cervical can-
cer burden globally, with a particular focus on SSA. This approach was
based on using most recent age-specific estimates of HIV prevalence
(UNAIDS) and relative risk (RR), accompanied by a widespread collection
of empirical data from cervical cancer series of known HIV status, in
order to inform and validate the methodology. Then, as a second step,
we applied this methodology to worldwide estimates of cervical cancer
incidence (GLOBOCAN 2020),1 to estimate HIV- and age-stratified cervi-
cal cancer burden at a country, regional and global level.
2 | METHODS
2.1 | Country-specific estimates of cervical cancer
and HIV prevalence
Age-specific population denominators, number of cervical cancer
cases and cervical cancer incidence (cases per 100 000 person years)
were extracted for 185 individual countries/territories described in
GLOBOCAN 2020.1
HIV prevalence estimates for women aged ≥15 years in 2019 were
acquired from UNAIDS for 175 of the 185 GLOBOCAN countries/terri-
tories. Age-specific denominators (population size) and numerators (num-
ber of WLHIV) were provided by UNAIDS in 5-year age groups and
were aggregated to produce HIV prevalence estimates for the age
groups 15 to 34, 35 to 44, 45 to 54 and ≥55 years (see justification
below). For the 10 remaining GLOBOCAN countries/territories, estimates
were completed with similarly aggregated age-specific HIV prevalence for
2019 published by the Institute for Health Metrics and Evaluation (IHME)
(http://ghdx.healthdata.org/gbd-results-tool).
2.2 | Age-specific RRs for HIV and cervical cancer
A systematic literature review and meta-analysis had previously identi-
fied 24 studies reporting RRs for cervical cancer in HIV infected
women.2 Of these 24 studies, only one provided RRs by age group.4 This
IARC-led case-control study, including 560 cervical cancer cases and
155 female non-cancer controls, was the largest identified by the meta-
analysis2 and was undertaken in an unscreened population in Rwanda
between 2012 and 2016. Of note, cART was already widespread in
Rwanda in this period (with growing availability from 2000; 81% of eligi-
ble PLHIV in Rwanda were estimated to be receiving cART by 2016).5
RRs were reported as odds ratios (ORs) (adjusted for province of resi-
dence), separately for the age groups 15 to 34 (OR = 33.8, 95% confi-
dence interval [CI], 9.3-122.6), 35 to 44 (6.8, 95% CI, 3.6-13.1), 45 to
54 (4.2, 95% CI, 2.1-8.3) and ≥55 years (2.4, 95% CI, 0.9-6.5).
2.3 | Empirical evidence on HIV prevalence in
cervical cancer, by age
The same literature review described above2 also identified 19 epidemio-
logical studies reporting HIV status in consecutively diagnosed series of
cervical cancer. These studies were all conducted in SSA, and authors
were invited to share data on HIV prevalence according to the age
groups ≤34, 35 to 44, 45 to 54 and ≥55 years. Relevant data were
obtained for 17 series from 13 countries: Botswana,6 Côte d'Ivoire,7,8
Kenya,9,10 Malawi,11 Mozambique,12 Nigeria,13 Rwanda,4 Senegal,14
South Africa,10,15,16 United Republic of Tanzania,17 Uganda,18 Zambia19
and Zimbabwe.20 We were unsuccessful in obtaining age-stratified data
from two additional eligible studies from Malawi.21,22
2.4 | Statistical analysis
For each of the 185 GLOBOCAN countries, and separately by age
groups ≤34, 35 to 44, 45 to 54 and ≥55 years, we estimated: (a) the
fraction of cervical cancer diagnosed among WLHIV (or HIV preva-
lence in cervical cancer), and (b) the fraction of cervical cancer attrib-
utable to HIV (or population-attributable fraction [PAF]), according to
the following formulas2:
1. HIV prevalence in cervical cancer = (HIV prevalence  RR)/
([1  HIV prevalence] + [HIV prevalence  RR]).
2. PAF= (HIV prevalence  [RR  1])/((1 + HIV prevalence [RR  1])).
For each country, and by age group, we calculated the number of new
cervical cancer cases (a) diagnosed among WLHIV, and (b) attributable
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to HIV, respectively, by multiplying these two respective fractions by
the number of new cervical cancer cases estimated from GLOBOCAN
2020. Country-specific estimates were aggregated worldwide,
according to WHO region and for the WHO African Region
(WHO/AFRO), and additionally according to UN sub-region, that is,
Eastern, Western, Central and Southern Africa, referred to collectively
here as SSA. Overall (ie, all ages combined), HIV prevalence and PAFs
were derived from the aggregate of age-specific numerators. Finally,
these estimates were applied to age-standardized incidence rates
(ASIRs) of cervical cancer, by HIV attribution status, per 100 000 per-
son years for four SSA sub-regions, as available in GLOBOCAN 2020.
All statistical analyses were conducted using Stata software
(Version 14.2) and world maps drawn using QGIS3 software.
3 | RESULTS
3.1 | Fractions of invasive cervical cancer
diagnosed among WLHIV and attributable to HIV
In 2020, 5.6% of global cervical cancer cases were estimated to be
diagnosed among WLHIV. However, this fraction varied substantially
according to age, being 15.5% for cervical cancer diagnosed at
≤34 years, 9.4% at 35 to 44, 5.6% at 45 to 54 and 1.7% at ≥55 years
(Table 1). The overall fraction of cervical cancer directly attributable
to HIV (ie, PAF) was 4.6% globally and was similarly inversely related
to age, being 15.1% at ≤34 years, 8.0% at 35 to 44, 4.2% at 45 to
54 and 1.0% at ≥55 years, respectively.
HIV was much more predominant in SSA (WHO/AFRO) (24.9%
of cervical cancer diagnosed in WLHIV, 20.4% attributable to HIV)
than in other WHO regions (1.3% and 1.1%, respectively), but con-
sistent age-specific decreases in HIV proportions were seen in all
world regions (Table 1). In SSA, estimated HIV prevalence was
51.8% among cervical cancer diagnosed at ≤34 years, 38.6% at
35 to 44, 27.1% at 45 to 54 years and 8.7% among women
≥55 years. The PAF in SSA was 50.2% in women ≤34 years, 32.9%
in 35 to 44 years, 20.6% in 45 to 54 years and 5.1% at ≥55 years
(Table 1).
Within SSA, the proportion of cervical cancer diagnosed in
WLHIV ranged from 53.8% in Southern Africa (PAF = 43.5%) down
to 10.7% (PAF = 8.9%) in Western Africa (Table 1). In Southern Africa,
estimated HIV positivity was 88.5% among cervical cancer diagnosed
at ≤34 years, 80.3% in 35 to 44 years, 62.6% in 45 to 54 years and
21.1% at ≥55 years, while PAFs were 85.9% in women ≤34 years,
68.5% in 35 to 44 years, 47.7% in 45 to 54 years and 12.3% at
≥55 years (Table 1).
TABLE 1 HIV prevalence and HIV-attributable fraction (PAF) in cervical cancer by age group, WHO regiona and sub-Saharan Africa
sub-regionb in 2020
Age group (years)


























World 15.5 15.1 9.4 8.0 5.6 4.2 1.7 1.0 5.6 4.6
Africa (AFRO) 51.8 50.2 38.6 32.9 27.1 20.6 8.7 5.1 24.9 20.4
Southern Africa 88.5 85.9 80.3 68.5 62.6 47.7 21.1 12.3 53.8 43.5
Eastern Africa 58.5 56.8 44.1 37.6 32.4 24.7 10.7 6.3 28.9 23.4
Central Africa 36.6 35.5 22.5 19.2 12.2 9.3 3.2 1.9 12.1 10.0
Western Africa 27.2 26.4 16.2 13.9 10.5 8.0 3.1 1.8 10.7 8.9
Non-AFRO regions 4.6 4.5 2.1 1.8 1.1 0.8 0.2 0.1 1.3 1.1
Europe (EURO) 8.4 8.2 3.6 3.1 1.4 1.0 0.3 0.2 2.3 2.0
South-East Asia
(SEARO)
6.1 5.9 2.4 2.1 1.1 0.8 0.3 0.2 1.2 1.0
Americas (PAHO) 5.1 5.0 2.9 2.4 1.9 1.4 0.5 0.3 1.9 1.6
Western Pacific
(WPRO)




1.8 1.7 0.9 0.8 0.5 0.4 0.0 0.0 0.5 0.4
Abbreviations: PAF, population-attributable fraction; SSA, sub-Saharan Africa; WLHIV, women living with HIV.
aWHO regions include Africa (AFRO), Americas (PAHO), East Mediterranean (EMRO), Europe (EURO), South-East Asia (SEARO) and Western
Pacific (WPRO).
bSSA sub-regions include Eastern Africa, Western Africa, Central Africa and Southern Africa.
cHIV prevalence in cervical cancer, equivalent to the fraction of cervical cancer diagnosed in WLHIV.
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Geographic and age-specific patterns of the fraction of cervical
cancer among WLHIV and the PAF are mapped in Figures 1 and 2,
respectively. Of note, for women diagnosed with cervical cancer at
≤34 years, HIV prevalence was estimated to be higher than 20% in a
number of individual countries outside SSA.
3.2 | Empirical data of HIV prevalence in cervical
cancer by age
As a validation exercise, Figure 3 compares the above-described IARC
age-specific estimates of HIV prevalence in cervical cancer in 2020
F IGURE 1 HIV prevalence in cervical cancer in 2020, by age group. The designations used and the presentation of the material in this article
do not imply the expression of any opinion whatsoever on the part of WHO and the IARC about the legal status of any country, territory, city, or
area, or of its authorities, or concerning the delimitation of its frontiers or boundaries
F IGURE 2 HIV-attributable fraction in cervical cancer in 2020, by age group. PAF, population-attributable fraction. The designations used
and the presentation of the material in this article do not imply the expression of any opinion whatsoever on the part of WHO and the IARC
about the legal status of any country, territory, city, or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries
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F IGURE 3 Variation in HIV prevalence in cervical cancer by age: comparison of IARC estimates and empirical data for selected countries.
IARC, International Agency for Research on Cancer
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with that of empirical data obtained from 17 studies of consecutively
diagnosed cervical cancer cases in 13 SSA countries. Most empirical
studies showed strong decreases in HIV prevalence in cervical cancer
according to age and were consistent with our 2020 estimates,
particularly those studies with a more recent median year of cervical
cancer diagnosis. For example, in Botswana, Malawi and Zimbabwe,
with mean years of cervical cancer diagnosis of 2018, 2015 and 2014,




HIV positive HIV negative
F IGURE 4 Burden of invasive cervical cancer cases according to HIV status, by world region. Non-AFRO includes WHO regions: Europe
(EURO), South-East Asia (SEARO), Americas (PAHO), East Mediterranean (EMRO) and Western Pacific (WPRO)
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age-specific estimates of HIV prevalence fell within the 95% CI of the
age-specific empirical data. For those SSA countries where empirical
studies were more historical (eg, Mozambique and Kenya, mean year
of cervical cancer diagnosis = 2001), IARC age-specific HIV preva-
lence estimates tended to be higher than those of the empirical data.
Finally, in South Africa, age-specific HIV prevalence in cervical cancer,
particularly those diagnosed above 45 years, tended to be higher in
series with later mean year of cervical cancer diagnosis.
3.3 | Absolute burden of invasive cervical cancer
cases diagnosed in WLHIV and attributable to HIV
By applying the fractions described in Table 1 to 2020 GLOBOCAN
estimates of cervical cancer, 33 694 cases were estimated to be diag-
nosed in WLHIV globally, and 27 822 of these to be directly attribut-
able to HIV (Figure 4). A vast majority of these cases, 27 637 and
22 645, respectively, were diagnosed in SSA. These included 6682
and 5431 cases in Southern Africa, 15 989 and 13 070 in Eastern
Africa, 1917 and 1588 in Central Africa and 3049 and 2556 in
Western Africa, respectively (Figure 4). A total of 6059 HIV-positive
and 5178 HIV-attributable cervical cancer were diagnosed in non-
AFRO regions, outside SSA (Figure 4). By describing numbers of cervi-
cal cancer cases according to HIV status and age, Figure 4 highlights
the shift in absolute burden of HIV-positive cervical cancer cases
toward younger ages, a phenomenon that is most apparent in South-
ern Africa. Absolute burden of cervical cancer by HIV attribution sta-
tus is shown at a country level in Table S1.
3.4 | Incidence rates of cervical cancer, by HIV
attribution status
Figure 5 describes age-specific incidence rates of cervical cancer in
the four UN African sub-regions according to HIV-attribution status,
as well as ASIRs. The incidence of non-HIV-attributable cervical cancer

























                                                                     ASIR
10.4         19.6        23.7          8.5         9.4
  8.0        32.5        72.2        127.7        30.7
18.3        52.1        95.9        136.2        40.1




























                                                                    ASIR
22.1           40.8          42.4          12.8       15.8
  3.6         18.8          46.5          90.9       20.6
25.7         59.5          88.9        103.7       36.4

























                                                                    ASIR
  3.8            6.8           7.0           2.2         3.2
  6.9        28.6         68.3        113.6       28.4





























                                                                    ASIR
  3.0            4.2           4.2           1.4         2.0
  8.5        26.0         47.9          75.8       11.9
11.5        30.2         52.1          77.2       13.9
(A) (B)
(C) (D)
F IGURE 5 Age-specific incidence rates of cervical cancer according to HIV-attribution status, by sub-Saharan Africa region (not shown for 0-
24 years as negligible [<1 per 100 000 in all regions]). ASIR, age-standardized incidence rate; pys, person years
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increased strongly and consistently with age in all regions. ASIRs of non-
HIV-attributable cervical cancer were highest in Eastern Africa (30.7
cases per 100 000 person years), followed by Central Africa (28.4) and
Southern Africa (20.6), and lowest (although still high on a global scale) in
Western Africa (11.9) (Figure 5). Age-specific incidence rates of HIV-
attributable cervical cancer, on the other hand, peaked in age groups
35 to 44 and 45 to 54 years, and ASIRs were highest in Southern Africa
(15.8 cases per 100 000 person years), followed by Eastern Africa (9.4),
and lowest in Central Africa (3.2) and Western Africa (2.0).
4 | DISCUSSION
Globally, in 2020, an estimated 6% of new cervical cancer cases were
diagnosed among WLHIV, and 5% were estimated to be directly
attributable to HIV infection, consistent with our previous estimates
for 2018.2 However, the age-specific approach we applied in this
effort goes further to demonstrate how the burden of HIV-
attributable cervical cancer falls disproportionately on younger
women. This phenomenon was most apparent, both in data obtained
from empirical series and in model estimates, in high HIV-attributable
cervical cancer burden settings in SSA. In Southern Africa, for exam-
ple, where more than half of all incident cervical cancer cases are diag-
nosed in WLHIV, 63% of HIV-attributable cervical cancer occurred in
women less than 45 years old, compared to only 17% of non-HIV-
attributable cervical cancer. Improved quantification of cervical cancer
burden by age and HIV status can inform appropriate resource alloca-
tion in cervical cancer prevention efforts, particularly in SSA.
A number of clinical series from SSA have reported mean age of
diagnosis of cervical cancer to be lower in HIV-infected than HIV-
uninfected women,13,15,19,20,22-27 most of which provided empirical
data to the present effort. However, robust estimates of RR for cervi-
cal cancer in WLHIV according to age only became available following
the publication of a large IARC-led case-control study of HIV and cer-
vical cancer in Rwanda.4 Our study was set in an SSA population in
the era of widespread access to cART. The age-specific ORs from our
study underpin the current approach and were observed to decrease
strongly by age, from OR = 34 (albeit with wide 95% CIs) in women
≤34 years, down to only 2.4 in women aged ≥55 years.
The validity of using age-specific RRs in our model was confirmed by
reproducing the HIV prevalence observed in contemporary cervical can-
cer cases series, in which HIV prevalence was also observed to decrease
strongly by age. Indeed, a model applying the single overall RR (ie, 6) to
age-specific HIV prevalence did not reproduce age-specific HIV preva-
lence in these recent cervical cancer series as precisely as an age-specific
RR approach (Figure S1). Interestingly, the age-specific RR approach was
able to reproduce contemporary empirical evidence in settings with
broadly different HIV prevalence (eg, Botswana and Côte d'Ivoire), clearly
illustrating that RRs are independent of HIV prevalence. Rather, the rea-
son RRs decrease so strongly by age is likely driven by the strong underly-
ing age-specific differences in cervical cancer risks in HIV-uninfected
women, as well as effects of competing HIV-related mortality at
older ages.
Indeed, temporal fluctuations in competing HIV-related mortality
have had an important historical influence on relative and absolute
cervical cancer risk in WLHIV in SSA. In the pre-cART era of the HIV
epidemic in SSA, a moment of severely reduced life expectancy for
WLHIV, observed RRs for cervical cancer tended to be non-significant
or relatively weak.24,28-31 Subsequently, in the era of wider access to
cART, RRs for cervical cancer in WLHIV in SSA have become increas-
ingly stronger as WLHIV live into the age groups when they are at risk
for developing cervical cancer.4,7 The RRs reported by Mpunga et al
used to inform our estimates were among the highest reported in SSA
to date,2 likely representing early roll out of cART in Rwanda. At the
other extreme, high levels of competing HIV-related mortality likely
explain the much lower HIV prevalence observed in historical pre-
cART empirical series of cervical cancer (eg, Mozambique with mean
year of diagnosis of 200112), compared to our recent estimates for
the same countries. These extreme changes in life expectancy and
cervical cancer risk in WLHIV, over the space of only a few decades,
illustrate why recent estimates, whether they be modeled or empirical,
are necessary to inform on the current burden of cervical cancer by
HIV status in SSA, in the era of widespread access to cART.
Throughout this work, we present two measures of the burden of
HIV-associated cervical cancer, namely that of cervical cancer diag-
nosed among WLHIV (equating to HIV prevalence among cases of
cervical cancer), and that of cervical cancer attributable to HIV (equat-
ing to the PAF). Both these measures are important for informing dif-
ferent aspects of cervical cancer prevention.
The burden of HIV-attributable cervical cancer gives a measure of
cancer cases directly due to HIV, that is, the number or proportion of
cases that could theoretically be avoided if HIV was removed from
the population. This measure, thus, brings into focus the importance
of reducing HIV transmission with respect to the goal of elimination
of cervical cancer in SSA.32,33 Earlier diagnosis of HIV infection and
timelier initiation of cART will also contribute to reducing the HIV-
attributable cervical cancer burden, as cART is known to significantly
lower the risk of cervical cancer among WLHIV.34 Of note, since HIV
and HPV share a common transmission route (sexual contact), there is
a potential for unmeasured confounding to translate into over-
estimated RRs, and thereby PAFs, particularly in settings with the
highest prevalence of HIV infection. Nevertheless, without any possi-
bility of controlling this interaction, these estimates provide the best
current approximation of the excess cervical cancer burden directly
attributable to HIV (and that would not exist in the absence of the
HIV epidemic).
Estimates of the proportion of cervical cancer cases diagnosed
among WLHIV, on the other hand, are unaffected by the above meth-
odological consideration. Furthermore, they can be directly validated
against empirically observed evidence, as illustrated in the current
exercise. This measure can be used to understand the extent to which
burden of disease falls on WLHIV, irrespective of direct causality, and
is, thus, particularly relevant for informing the design, and potential
impact, of cervical cancer prevention services targeted to WLHIV.
In recognition of the increased risk of cervical cancer in WLHIV, it
is widely recommended for cervical screening of WLHIV to start at an
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earlier age, and for subsequent screening intervals to be shorter for
WLHIV than for the general female population.35 In SSA, and some
other settings without population-level cervical cancer screening pro-
grams, this has led to several cervical cancer screening initiatives that
primarily target WLHIV, most notably those funded by PEPFAR.36
This approach can be facilitated by WLHIV undergoing regular follow-
up in the healthcare system. Furthermore, investment in new screen-
ing infrastructures for WLHIV can be a catalyst for subsequent expan-
sion of these services to the wider HIV-uninfected population.37
Thus, age-specific burden of cervical cancer in WLHIV vs that in HIV-
uninfected women at a population level can help inform the appropri-
ate lower age limit of WLHIV-targeted cervical cancer screening, as
well as assess the relative impact of a targeted approach for WLHIV
vs that of a more general population program.32,38
The WHO global strategy to eliminate cervical cancer is ultimately
underpinned by widespread implementation of HPV vaccination pro-
grams. Vaccination prior to sexual activity is expected to prevent cer-
vical cancer in vaccinated cohorts, but this impact will not occur for a
number of decades and will first be seen on cervical cancer burden at
youngest ages.39 Vaccine impact should be witnessed irrespective of
HIV status, given that HIV is not a direct carcinogen, but rather acts
via impaired immunity to worsen the carcinogenic effect of HR HPV.
Hence, increasing HPV vaccination coverage in countries with a high
burden of cervical cancer, particularly those with a double burden of
HPV and HIV, remains a critical priority. This is especially the case as
these same high burden countries are often those where population-
wide cervical screening coverage is low.40
Of note, all ages combined, overall burden estimates of HIV-
associated cervical cancer at a country, regional and global level for
2020 are materially unchanged from those of 2018.2 For example, the
approximate number of cervical cancers diagnosed in WLHIV globally
was estimated at 33 000 in 2018 and 34 000 in 2020 and 28 000 for
WHO/AFRO in both years. Indeed, the nature of GLOBOCAN data
on cervical cancer burden (and, to a certain extent also that of
UNAIDS HIV prevalence data) means that estimates from subsequent
editions should not be considered as time trends, but rather as best
possible current estimates given continual data improvements. Of
note, many SSA settings do not have population-based cancer regis-
tries, and GLOBOCAN estimates are often derived from hospital can-
cer series, mortality data, or are based on data from neighboring
countries. As in previous estimates for 2018,2 we show ASIR of cervi-
cal cancer by HIV-attribution status and additionally show, for the first
time, age-specific incidence rates by HIV-attribution status. These
measures are useful to compare the contribution of HIV to
population-level cervical cancer burden across different SSA
populations, in a standardized format.
It should be noted that HIV-attributable cancer incidence among
all women (as shown here) is not the same as cervical cancer incidence
in WLHIV. Few data exist on age-specific cervical cancer incidence in
WLHIV in SSA. However, some preliminary data have been recently
reported by a large linkage study in South Africa41 describing, as
expected, strongly increasing cervical cancer incidence in WLHIV by
age: from 29 cases per 100 000 persons years for WLHIV aged 20 to
29 years up to 242 cases per 100 000 person years at 60 to
69 years.41 Similar measures are not easily calculable from our
approach, due to difficulties in establishing person years by HIV status
at a population level.
The fact that there were no relevant empirical cervical cancer
series against which to validate our HIV estimates outside SSA is a
limitation of this analysis. In the United States, however, studies
based on linkage of HIV/AIDS and cancer registries have also
shown the contribution of HIV to cervical cancer to be shifted
toward younger ages. In a setting of low HIV prevalence and wide-
spread cervical screening, the proportion of cervical cancer in 1980
to 2007 in the United States, diagnosed among women with AIDS,
has been estimated at 0.8%, 0.6% and 0.04% at ages 0 to 29, 30 to
59 and ≥60 years, respectively.42 These estimates compare to
2.8%, 1.7%, 1.3% and 0.3% for ≤34, 35 to 44, 45 to 54 and
≥55 years diagnosed among WLHIV in the United States in our
2020 estimates.
In conclusion, the burden of cervical cancer associated with
HIV is strongly shifted toward women at younger ages and has
been changing with the evolution of the HIV epidemic in SSA.
Thus, locally relevant data on the age-specific contribution of HIV
to cervical cancer should be used to better design prevention pro-
grams, particularly in settings in SSA hit by a double burden of
HPV and HIV. To keep evidence up to date, SSA countries should
be encouraged to document HIV status and cART use in clinical
cervical cancer series. This should be feasible given that cervical
cancer is an AIDS-defining condition, and that HIV-testing is
becoming increasingly widespread. These data will be highly infor-
mative for monitoring progress toward the WHO cervical cancer
elimination goal in SSA.
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